NasdaqCM:IDXG

Stock Analysis Report

Interpace Diagnostics Group

Executive Summary

Interpace Diagnostics Group, Inc. develops and commercializes molecular diagnostic tests to detect genetic alterations associated with gastrointestinal, endocrine, and lung cancers.

Snowflake

Fundamentals

High growth potential with adequate balance sheet.


Similar Companies

Share Price & News

How has Interpace Diagnostics Group's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-3.1%

IDXG

4.6%

US Healthcare

2.3%

US Market


1 Year Return

-42.2%

IDXG

-8.5%

US Healthcare

5.6%

US Market

Return vs Industry: IDXG underperformed the US Healthcare industry which returned -8.5% over the past year.

Return vs Market: IDXG underperformed the US Market which returned 5.6% over the past year.


Shareholder returns

IDXGIndustryMarket
7 Day-3.1%4.6%2.3%
30 Day-4.0%-0.1%-1.0%
90 Day-6.1%-4.5%-0.7%
1 Year-42.2%-42.2%-7.1%-8.5%7.9%5.6%
3 Year-44.5%-44.5%31.9%26.5%45.6%36.3%
5 Year-95.5%-95.5%63.7%53.9%65.8%47.6%

Price Volatility Vs. Market

How volatile is Interpace Diagnostics Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Interpace Diagnostics Group undervalued compared to its fair value and its price relative to the market?

0.99x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate IDXG's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate IDXG's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IDXG is unprofitable, so we can't compare its PE Ratio to the Healthcare industry average.

PE vs Market: IDXG is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate IDXG's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IDXG is good value based on its PB Ratio (1x) compared to the US Healthcare industry average (2.5x).


Next Steps

Future Growth

How is Interpace Diagnostics Group forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

73.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IDXG is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).

Earnings vs Market: IDXG is forecast to become profitable over the next 3 year, which is considered above average market growth.

High Growth Earnings: IDXG's loss is forecast to worsen by 0% next year.

Revenue vs Market: IDXG's revenue (33.5% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: IDXG's revenue (33.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if IDXG's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Interpace Diagnostics Group performed over the past 5 years?

8.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: IDXG is unprofitable, but has reduced losses over the past 5 years at a rate of 8.3% per year.

Accelerating Growth: Unable to compare IDXG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IDXG is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (5.3%).


Return on Equity

High ROE: IDXG has a negative Return on Equity (-51.37%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: IDXG is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: IDXG is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Interpace Diagnostics Group's financial position?


Financial Position Analysis

Short Term Liabilities: IDXG's short term assets ($19.2M) exceeds its short term liabilities ($11.0M)

Long Term Liabilities: IDXG's short term assets (19.2M) exceeds its long term liabilities (8.5M)


Debt to Equity History and Analysis

Debt Level: IDXG is debt free.

Reducing Debt: IDXG had no debt 5 years ago.


Balance Sheet

Inventory Level: IDXG has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if IDXG's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IDXG has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: IDXG has less than a year of cash runway if free cash flow continues to grow at historical rates of 6.2% each year.


Next Steps

Dividend

What is Interpace Diagnostics Group's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.6%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate IDXG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate IDXG's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if IDXG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IDXG's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IDXG's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Interpace Diagnostics Group's salary, the management and board of directors tenure and is there insider trading?

3.3yrs

Average management tenure


CEO

Jack Stover (66yo)

3.3yrs

Tenure

US$1,307,880

Compensation

Mr. Jack E. Stover, CPA has been the Chief Executive Officer and President of Interpace Diagnostics Group, Inc. since June 21, 2016. Mr. Stover has been Chief Executive Officer of Zebec Therapeutics LLC (Z ...


CEO Compensation Analysis

Compensation vs. Market: Jack's total compensation ($USD1.31M) is about average for companies of similar size in the US market ($USD493.00K).

Compensation vs Earnings: Jack's compensation has been consistent with company performance over the past year.


Management Age and Tenure

3.3yrs

Average Tenure

58.5yo

Average Age

Experienced Management: IDXG's management team is considered experienced (3.3 years average tenure).


Board Age and Tenure

3.8yrs

Average Tenure

65.5yo

Average Age

Experienced Board: IDXG's board of directors are considered experienced (3.8 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Jack Stover (66yo)

    CEO, President & Director

    • Tenure: 3.3yrs
    • Compensation: US$1.31m
  • Greg Richard (52yo)

    Senior VP & Chief Commercial Officer

    • Tenure: 5.5yrs
    • Compensation: US$619.24k
  • Sydney Finkelstein

    Chief Scientific Officer

    • Tenure: 0yrs
  • Patrick Kane

    VP & Corporate Controller

    • Tenure: 10.3yrs
  • Jim Early (65yo)

    CFO, Secretary & Treasurer

    • Tenure: 3yrs
    • Compensation: US$489.27k
  • Thomas Freeburg (51yo)

    Chief Accounting Officer

    • Tenure: 1.6yrs
  • Glenn Gershon

    Senior Vice President of Operations

    • Tenure: 0yrs

Board Members

  • Joe Keegan (65yo)

    Director

    • Tenure: 3.8yrs
    • Compensation: US$77.13k
  • Steve Sullivan (72yo)

    Chairman of the Board

    • Tenure: 3.8yrs
    • Compensation: US$87.13k
  • Eric Lev

    Director

    • Tenure: 0.3yrs
  • Jack Stover (66yo)

    CEO, President & Director

    • Tenure: 3.3yrs
    • Compensation: US$1.31m
  • Felice Schnoll-Sussman (49yo)

    Director

    • Tenure: 2.1yrs
    • Compensation: US$57.13k

Company Information

Interpace Diagnostics Group, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Interpace Diagnostics Group, Inc.
  • Ticker: IDXG
  • Exchange: NasdaqCM
  • Founded: 1986
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$30.490m
  • Shares outstanding: 38.20m
  • Website: https://www.interpacediagnostics.com

Number of Employees


Location

  • Interpace Diagnostics Group, Inc.
  • Morris Corporate Center 1
  • Building C
  • Parsippany
  • New Jersey
  • 7054
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IDXGNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDMay 1998
PF41DB (Deutsche Boerse AG)YesCommon StockDEEURMay 1998

Biography

Interpace Diagnostics Group, Inc. develops and commercializes molecular diagnostic tests to detect genetic alterations associated with gastrointestinal, endocrine, and lung cancers. It offers PancraGEN, a  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/16 23:42
End of Day Share Price2019/10/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.